Drugmakers go nuclear, continuing push into radiopharmaceuticals

Elie Dolgin • June 10, 2021

With late-stage trial success, venture funding and next-generation alpha emitters on the way, targeted radiotherapy drugs are finally “getting the attention they deserve.”

The clinical success of the first targeted radiopharmaceutical designed to combat a common type of cancer looks poised to help bring the once-fringe treatment modality into the medical mainstream.


Earlier this month, Novartis reported phase 3 data from its VISION trial showing that men with metastatic castration-resistant prostate cancer lived longer when, in addition to standard-of-care treatments, they received the company’s 177Lu-PSMA-617, a small-molecule drug that delivers radiation-emitting lutetium isotopes to cells expressing prostate-specific membrane antigen (PSMA).


Continue reading at Nature Biotechnology.

Girl jumping with arms bandaged
By Elie Dolgin August 27, 2025
Fresh treatments shift the focus from symptom management to repair.
By Elie Dolgin August 27, 2025
Smart algorithms take aim at antimicrobial resistance.